Multiple myelomaNews & Research
15 curated articles for Multiple myeloma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Expert opinion on biological therapy Apr 22, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) are among the backbones of treatment for relapsed/refractory multiple myeloma (RRMM). Beyond current standard-of-care regimens, the roles of mAbs/ADCs are evolving associated with advances in first-line therapy, emerging data on additi...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- American journal of hematology Apr 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application. To address gaps in evidence, the 2025 Bridging the Gaps Consensus Conference convened 16 US MM experts who reviewed data, debated controversies, and vot...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Seminars in hematology Apr 21, 2026
Targeted immunoPET imaging of multiple myeloma.
Current standard of care methods of imaging multiple myeloma disease burden are suboptimal. For example, fluorodeoxyglucose-(FDG)-PET/CT may fail to detect up to 50% of myeloma lesions. Immunologically based positron emission tomography (immunoPET) is an imaging modality allowing detecting of multip...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Leukemia & lymphoma Apr 21, 2026
Targeting the FOXM1/BUB1B signaling network in multiple myeloma: mechanistic insights and therapeutic potential.
Multiple myeloma (MM) is a plasma cell cancer characterized by genomic instability and drug resistance. The FOXM1 transcription factor and the BUB1B kinase are pivotal drivers of this malignancy. FOXM1 promotes cell cycle progression and is upregulated by oncogenic pathways like mitogen-activated pr...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- International journal of hematology Apr 15, 2026
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study.
Talquetamab is the first G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We report the first efficacy and safety results of talquetamab in Japanese patients enrolled as a separate coh...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Blood Apr 2, 2026
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).
Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some progress early after initial response. To investigate this, we examined 44 whole-genome and whole-exome...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Internal medicine (Tokyo, Japan) Mar 28, 2026
Birt-Hogg-Dubé Syndrome and Multiple Myeloma?
Birt-Hogg-Dubé Syndrome and Multiple Myeloma?
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Nature reviews. Clinical oncology Mar 26, 2026
Diagnosis, risk stratification and management of smouldering multiple myeloma.
New therapies have markedly improved survival outcomes for patients with multiple myeloma (MM). However, the onset of active disease, as defined by the 2014 International Myeloma Working Group SLiM-CRAB criteria, is often linked to substantial and irreversible morbidity. MM always develops from an a...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Blood cancer journal Mar 20, 2026
Toward a cure for multiple myeloma within a decade.
Multiple myeloma (MM), long viewed as incurable, is entering a transformative era marked by deeper remissions, prolonged survival, and the realistic prospect of cure. The greatest opportunity lies at diagnosis, before genomic heterogeneity and immune escape limit therapeutic impact. High-risk smolde...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- American family physician Mar 16, 2026
Multiple Myeloma: Diagnosis and Treatment.
Multiple myeloma, a hematologic malignancy of plasma cells characterized by excessive monoclonal protein production, accounts for 36,000 new cancer diagnoses annually in the United States. The median age at diagnosis is 69 years. Multiple myeloma may present with symptoms, such as bone pain, fatigue...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Physiological reports Mar 12, 2026
Sleep quality and sleepiness in adults with multiple myeloma. Is melatonin a potential treatment?
Sleep disturbances significantly impact quality of life in cancer patients, yet remain poorly characterized in multiple myeloma (MM). This observational study aimed to characterize sleep profiles in MM patients and evaluate the therapeutic potential of exogenous melatonin. We assessed 46 MM p...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Blood cancer discovery Mar 6, 2026
Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.
The standard of care for multiple myeloma has rapidly evolved to include immune-based therapies. However, achieving durable immune control and long-term survival, particularly in high-risk patients, remains difficult. In this article, we review the immune effects of existing and emerging therapies, ...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- European journal of haematology Feb 24, 2026
Extramedullary Multiple Myeloma.
Extramedullary disease (EMD) of multiple myeloma (MM) is a critical indicator of disease progression, with a complex pathophysiology involving tumor microenvironment dysregulation, chromosomal abnormalities, and aberrant signaling pathway activation. Advances in detection technologies have significa...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Advanced science (Weinheim, Baden-Wurttemberg, Germany) Feb 13, 2026
Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-c...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
- Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy Feb 6, 2026
DEAF1 confers resistance to adriamycin-induced apoptosis and pyroptosis in multiple myeloma.
Transcriptional dysregulation by aberrant transcription factors (TFs) is a key driver of drug resistance. Resistance to adriamycin (ADR) frequently develops following first-line treatment for multiple myeloma (MM). This study aims to identify novel TFs associated with ADR resistance in MM and to elu...
Why it matters: Recent peer-reviewed research on Multiple myeloma that may be relevant for patients and caregivers.
More on Multiple myeloma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.